Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial
The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone. However, information about its long-term use in this population is limited. OBJECTIVE: To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH and prediabetes or T2DM. DESIGN: Randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT00994682). SETTING: University hospital. PARTICIPANTS: Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics. INTERVENTION: All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment. MEASUREMENTS: The primary outcome was a reduction of at least 2 points in the nonalcoholic fatty liver disease activity score in 2 histologic categories without worsening of fibrosis. Secondary outcomes included other histologic outcomes, hepatic triglyceride content measured by magnetic resonance and proton spectroscopy, and metabolic parameters. RESULTS: Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P < 0.001 for each). Pioglitazone treatment also was associated with improvement in individual histologic scores, including the fibrosis score (treatment difference, -0.5 [CI, -0.9 to 0.0]; P = 0.039); reduced hepatic triglyceride content from 19% to 7% (treatment difference, -7 percentage points [CI, -10 to -4 percentage points]; P < 0.001); and improved adipose tissue, hepatic, and muscle insulin sensitivity (P < 0.001 vs. placebo for all). All 18-month metabolic and histologic improvements persisted over 36 months of therapy. The overall rate of adverse events did not differ between groups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo). LIMITATION: Single-center study. CONCLUSION: Long-term pioglitazone treatment is safe and effective in patients with prediabetes or T2DM and NASH. PRIMARY FUNDING SOURCE: Burroughs Wellcome Fund and American Diabetes Association.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Benefi cial effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been seen with pioglitazone (200,201).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“weight gain was also significantly higher in the treatment group [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“a randomized controlled trial including 101 patients with either pre‐ or type 2 diabetes found that 51% in the Pioglitazone group (45 mg/day) had resolution of NASH and 58% achieved the primary outcome of the study (reduction of ≥2 NAS points in two histologic categories without worsening of fibrosis), both significantly [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“Pioglitazone treatment was also associated with a significant improvement in fibrosis score.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Self-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 2×
“5) mg/dL 149 (36) 153 (34) 1 (−18 to 19) LDL cholesterol level 0.”
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 3×
“Additional secondary outcomes included the following: 1) fasting plasma glucose, fasting plasma insulin, FFA, hemoglobin A1c, fasting plasma lipid profile, adiponectin, and cytokeratin-18 concentrations; 2) total body fat percentage, measured by DXA; 3) hepatic triglyceride content, measured by magnetic resonance and…”
Self-citationLoomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Mofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,201
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“001 Fibrosis ≥1-point improvement, n (%) 13 (25) 20 (39) 14 (−6 to 34) 0.”
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Research works printed but not linked: 1
- Bril F, 2015, Diabetes, 64, A337
Cited by
Items 201–300 of 1,001
Edwards, C., & Cusi, K. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.007 · Cited by 120
Self-citationA review of non‐alcoholic fatty liver disease in non‐obese and lean individuals
Ahadi, M., Molooghi, K., Masoudifar, N., Namdar, A. B., Vossoughinia, H., & Farzanehfar, M. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15353 · Cited by 107
Glass, O., Filozof, C., Noureddin, M., Berner-Hansen, M., Schabel, E., Omokaro, S. O., Schattenberg, J. M., Barradas, K., Miller, V., Francque, S., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.030 · Cited by 89
Bril, F., McPhaul, M. J., Caulfield, M. P., Castille, J. M., Poynard, T., Soldevila‐Pico, C., Clark, V., Firpi-Morell, R. J., Lai, J., & Cusi, K. J. (2019) · Journal of Investigative Medicine · doi:10.1136/jim-2018-000864 · Cited by 97
Self-citationWhy Do So Many Nonalcoholic Steatohepatitis Trials Fail?
Ratziu, V., & Friedman, S. L. (2023) · Gastroenterology · doi:10.1053/j.gastro.2020.05.046 · Cited by 88
Athyros, V. G., Pοlyzos, S. A., Kountouras, J., Katsiki, N., Anagnostis, P. G., Doumas, M. N., & Mantzoros, C. S. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190405164313 · Cited by 90
Wong, C., Lee, M. H., Yaow, C. Y. L., Chin, Y. H., Goh, X. L., Ng, C. H., Lim, A. Y. L., Muthiah, M. D., & Khoo, C. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.609110 · Cited by 86
Diabetes medications and risk of HCC
Plaz Torres, M. C., Jaffe, A., Perry, R., Marabotto, E., Strazzabosco, M., & Giannini, E. G. (2022) · Hepatology · doi:10.1002/hep.32439 · Cited by 86
Della Pepa, G., Russo, M., Vitale, M., Carli, F., Vetrani, C., Masulli, M., Riccardi, G., Vaccaro, O., Gastaldelli, A., Rivellese, A. A., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108984 · Cited by 84
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Francque, S., & Vonghia, L. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00898-6 · Cited by 84
“Glitazones have been approved for the treatment of diabetes but were also shown to be effective in improving histological lesions of NASH in several trials [37, 44, 45].”
BackgroundManagement of NAFLD in primary care settings
Wong, V. W. S., Zelber‐Sagi, S., Cusi, K., Carrieri, P., Wright, E., Crespo, J., & Lazarus, J. V. (2022) · Liver International · doi:10.1111/liv.15404 · Cited by 81
Self-citationNASH drug treatment development: challenges and lessons
Tilg, H., Byrne, C. D., & Targher, G. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00159-0 · Cited by 81
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 96
“In the placebo-controlled, phase 3 PROVIDE trial, the use of pemafibrate led to a significant decrease of fasting TG compared to placebo ( p 0.001) [76], an effect that was stable during the open-label extension period [177].”
InfluentialPark, J., Kim, G., Kim, B., Han, K., Kwon, S. Y., Park, S., Lee, Y., Jin, S., & Kim, J. H. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01483-y · Cited by 83
Ivashkin, V. T., Maevskaya, M. V., Жаркова, М. С., Kotovskaya, Y. V., Ткачева, О. Н., Troshina, E. A., Shestakova, M. V., Maev, I. V., Breder, V. V., Geyvandova, N. I., et al. (2022) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2022-32-4-104-140 · Cited by 99
Advances in the management of type 2 diabetes in adults
Galindo, R. J., Trujillo, J. M., Wang, C. C. L., & McCoy, R. G. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000372 · Cited by 109
Vatner, D. F., Goedeke, L., Camporez, J.-P. G., Lyu, K., Nasiri, A. R., Zhang, D., Bhanot, S., Murray, S. F., Still, C. D., Gerhard, G. S., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4579-1 · Cited by 76
Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities
Manka, P., Zeller, A., & Syn, W.-K. (2019) · Drugs · doi:10.1007/s40265-019-01126-9 · Cited by 76
Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease
Hadi, H. E., Vincenzo, A. D., Vettor, R., & Rossato, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092215 · Cited by 107
“Pioglitazone is another family of insulin-sensitizing agents that have been associated with improvements in histological findings in NAFLD [58].”
BackgroundDiabetes drugs for nonalcoholic fatty liver disease: a systematic review
Blazina, I., & Selph, S. (2019) · Systematic Reviews · doi:10.1186/s13643-019-1200-8 · Cited by 74
Liu, J., Liu, J., Mu, W., Ma, Q., Zhai, X., Jin, B., Liu, Y., & Zhang, N. (2024) · ACS Nano · doi:10.1021/acsnano.4c02380 · Cited by 74
A critical review of endpoints for non-cirrhotic NASH therapeutic trials
Ratziu, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.12.001 · Cited by 74
Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease
Choudhary, N. S., Kumar, N., & Duseja, A. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.06.004 · Cited by 73
Younossi, Z. M. (2018) · Liver Transplantation · doi:10.1002/lt.25003 · Cited by 73
Mantovani, A., Turino, T., Lando, M. G., Gjini, K., Byrne, C. D., Zusi, C., Ravaioli, F., Colecchia, A., Maffeis, C., Salvagno, G., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.11.004 · Cited by 71
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 77
Self-citationTanajewski, L., Harris, R., Harman, D. J., Aithal, G. P., Card, T. R., Gkountouras, G., Berdunov, V., Guha, I. N., & Elliott, R. A. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015659 · Cited by 71
Seko, Y., Sumida, Y., Sasaki, K., Itoh, Y., Iijima, H., Hashimoto, T., Ishii, S., & Inagaki, N. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1364-8 · Cited by 70
Lee, S. M., Pusec, C. M., Norris, G. H., Jesus, A. D., Díaz‐Ruiz, A., Muratalla, J. T., Sarmento‐Cabral, A., Guzman, G., Layden, B. T., & Córdoba‐Chacón, J. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.003 · Cited by 77
“Recently, a trial that used pioglitazone in NASH patients improved liver histology after 18 months of treatment, but the extension of the study did not promote additional reductions in steatosis.(4) Similarly, in mice fed a HFCF diet, long-term treatment with pioglitazone increased insulin sensitivity and partially re…”
ResultInflammation is independent of steatosis in a murine model of steatohepatitis
Wang, W., Xu, M., Cai, Y., Zhou, Z., Cao, H., Mukhopadhyay, P., Pacher, P., Zheng, S., Gonzalez, F. J., & Gao, B. (2017) · Hepatology · doi:10.1002/hep.29129 · Cited by 70
Musolino, V., Gliozzi, M., Bombardelli, E., Nucera, S., Carresi, C., Maiuolo, J., Mollace, R., Paone, S., Bosco, F., Scarano, F., et al. (2020) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2020.02.004 · Cited by 74
Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus
Lake, J. E., Overton, T., Naggie, S., Sulkowski, M., Loomba, R. S., Kleiner, D. E., Price, J. C., Chew, K. W., Chung, R. T., & Corey, K. E. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.10.018 · Cited by 78
Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease
Campos-Murguía, A., Ruiz‐Margáin, A., González-Regueiro, J. A., & Macías‐Rodríguez, R. U. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i39.5919 · Cited by 85
Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis
Ng, C. H., Xiao, J., Lim, W. H., Chin, Y. H., Yong, J. N., Tan, D. J. H., Tay, P., Syn, N., Foo, R., Chan, M., et al. (2022) · Hepatology · doi:10.1002/hep.32315 · Cited by 69
ISPAD Clinical Practice Consensus Guidelines 2024: Type 2 Diabetes in Children and Adolescents
SHAH, A. S., Pérez, M. B., CHANG, N. T., Fu, J., Hannon, T. S., Kelsey, M. M., Peña, A. S., Pinhas‐Hamiel, O., Urakami, T., Wicklow, B. A., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543033 · Cited by 100
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Cusi, K. (2020) · Diabetes Care · doi:10.2337/dci19-0064 · Cited by 67
Self-citationBeneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kim, K., & Lee, B. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0137 · Cited by 73
“On the contrary, another RCT was conducted in 101 patients with biopsy-proven NASH to investigate whether 45 mg/day pioglitazone treatment for 18 months could achieve the primary outcome with an improvement of at least two points in NAFLD activity score (NAS) and no worsening of fibrosis.(35) Pioglitazone treatment sh…”
ResultBajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s004 · Cited by 133
Role of HSD17B13 in the liver physiology and pathophysiology
Su, W., Mao, Z., Liu, Y., Zhang, X., Zhang, W., Gustafsson, J.-Α., & Guan, Y. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.10.014 · Cited by 85
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Sumida, Y., Yoneda, M., Tokushige, K., Kawanaka, M., Fujii, H., Yoneda, M., Imajo, K., Takahashi, H., Eguchi, Y., Ono, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061907 · Cited by 68
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Mahjoubin‐Tehran, M., Vincentis, A. D., Mikhailidis, D. P., Atkin, S. L., Mantzoros, C. S., Jamialahmadi, T., & Sahebkar, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101049 · Cited by 73
“Common a dverse events were musculoskeletal, respiratory/otolaryngologic, and gastrointestinal b ut there was no difference between the pioglitazone and placebo groups [49].”
BackgroundLin, R., Sun, Q., Xin, X., Ng, C. H., Valenti, L. V. C., Hu, Y., Zheng, M., & Feng, Q. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156043 · Cited by 73
Diagnosis and Management of Nonalcoholic Fatty Liver Disease
Paul, S., & Davis, A. M. (2018) · JAMA · doi:10.1001/jama.2018.17365 · Cited by 65
Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
Qu, W., Ma, T., Cai, J., Zhang, X., Zhang, P., She, Z., Wan, F., & Li, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.761538 · Cited by 76
Kalavalapalli, S., Bril, F., Koelmel, J. P., Abdo, K., Guingab, J., Andrews, P., Li, W.-Y., Jose, D., Yost, R. A., Frye, R. F., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00023.2018 · Cited by 66
Self-citationLv, X., Dong, Y., Hu, L., Lu, F., Zhou, C., & Qin, S. (2020) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.163 · Cited by 65
“A total of 6313 participants were studied, with a mean duration of 37 (12-144) weeks.”
Background(2021) · doi:10.1007/s12072-021-10242-2 · Cited by 64
An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
Giglio, R. V., Παπάνας, Ν., Rizvi, A. A., Ciaccio, M., Patti, A. M., Ilias, Ι., Stoian, A. P., Sahebkar, A., Janež, A., & Rizzo, M. (2022) · Medicina · doi:10.3390/medicina58101475 · Cited by 80
Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease
Grattagliano, I., Montezinho, L. P., Oliveira, P. J., Frühbeck, G., Gómez‐Ambrosi, J., Montecucco, F., Carbone, F., Wieckowski, M. R., Wang, D. Q. ‐., & Portincasa, P. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.11.020 · Cited by 70
“Pioglitazone, in fact, improved liver histology in these patients [125].”
BackgroundNAFLD/NASH in patients with type 2 diabetes and related treatment options
Radaelli, M. G., Martucci, F., Perra, S., Accornero, S., Castoldi, G., Lattuada, G., Manzoni, G., & Perseghin, G. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0799-3 · Cited by 67
Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?
Glass, L. M., Hunt, C. M., Fuchs, M. A., & Su, G. L. (2019) · Europe PMC (PubMed Central) · Cited by 78
Phase 3 drug pipelines in the treatment of non‐alcoholic steatohepatitis
Sumida, Y., Okanoue, T., Nakajima, A., & Japan Study Group of NAFLD (JSG‐NAFLD) (2019) · Hepatology Research · doi:10.1111/hepr.13425 · Cited by 65
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Reinson, T., Buchanan, R. M., & Byrne, C. D. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0348 · Cited by 75
Shannon, C. E., Ragavan, M., Palavicini, J. P., Fourcaudot, M. J., Bakewell, T. M., Valdez, I., Ayala, I., Jin, E. S., Madesh, M., Han, X., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101154 · Cited by 68
“However, improvements in insulin sensitivity [12,59] and”
BackgroundWong, C., Yaow, C. Y. L., Ng, C. H., Chin, Y. H., Low, Y. F., Lim, A. Y. L., Muthiah, M. D., & Khoo, C. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.609135 · Cited by 69
Maevskaya, M. V., Kotovskaya, Y. V., Ivashkin, V. T., Ткачева, О. Н., Troshina, E. A., Shestakova, M. V., Breder, V. V., Geyvandova, N. I., Doshchitsin, V. L., Dudinskaya, Е. N., et al. (2022) · Terapevticheskii arkhiv · doi:10.26442/00403660.2022.02.201363 · Cited by 70
Role of liver sinusoidal endothelial cell in metabolic dysfunction-associated fatty liver disease
He, Q., He, W., Dong, H., Guo, Y., Yuan, G., Shi, X., Wang, D., & Lu, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01720-9 · Cited by 73
Lemoinne, S., & Friedman, S. L. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.09.006 · Cited by 60
Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
Budd, J., & Cusi, K. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.01.007 · Cited by 60
Self-citationThe Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease
Yang, Z., Danzeng, A., Liu, Q., Zeng, C., Xu, L., Mo, J., Ciren, P., Wang, X., Wang, C., Zhang, B., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87305 · Cited by 66
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
Budd, J. T., & Cusi, K. J. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01349-1 · Cited by 61
Self-citationTLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism
Shepard, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.613639 · Cited by 64
Novel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus
Sumida, Y., Seko, Y., Yoneda, M., & Japan Study Group of NAFLD (JSG‐NAFLD) (2017) · Hepatology Research · doi:10.1111/hepr.12856 · Cited by 60
Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease
Pelusi, S., & Valenti, L. (2019) · Liver International · doi:10.1111/liv.13972 · Cited by 57
Diabetes and metabolic dysfunction-associated fatty liver disease
Davis, T. M. E. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154868 · Cited by 62
Cheon, S. Y., & Song, J. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00836-0 · Cited by 61
Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
Sharma, M., Premkumar, M., Kulkarni, A. V., Kumar, P., Reddy, D. N., & Rao, N. P. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00055 · Cited by 61
Baumann, A., Burger, K., Brandt, A., Staltner, R., Jung, F., Rajcic, D., Pisarello, M. J. L., & Bergheim, I. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155233 · Cited by 56
Bril, F., Barb, D., Lomonaco, R., Lai, J., & Cusi, K. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.018 · Cited by 55
Diabetes as a risk factor for MASH progression
Gancheva, S., Roden, M., & Castéra, L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111846 · Cited by 65
Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease
Jeznach-Steinhagen, A. E., Ostrowska, J., Czerwonogrodzka–Senczyna, A., Boniecka, I., Shahnazaryan, U., & Kuryłowicz, A. (2019) · Medicina · doi:10.3390/medicina55050166 · Cited by 57
Arrese, M., Barrera, F., Triantafilo, N., & Arab, J. P. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1649981 · Cited by 54
Dhir, G., & Cusi, K. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000554 · Cited by 53
Self-citationNonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Kim, K., Lee, B., Kim, Y. J., Lee, D. H., Soo, B., & Park, C. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0034 · Cited by 59
Wang, Z., Huiqing, D., Zhao, Y., Ren, Y., Ma, C., Chen, H., Li, M., Tian, J., Xue, C., Long, G., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1111430 · Cited by 71
“In terms of the research design, the doses of pioglitazone medication varied among studies (15 (37), 30 (36, 38–40), and 45 mg/day (11, 12)), as well as the treatment courses (3 (37), 6 (11, 40), 12 (36, 39), 18 (12), and 24 months (38)).”
BackgroundResultInfluentialEzhilarasan, D. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155912 · Cited by 57
Mucinski, J. M., Salvador, A. F., Moore, M. P., Fordham, T. M., Anderson, J. M., Shryack, G. E., Cunningham, R. P., Lastra, G., Gaballah, A. H., Diaz‐Arias, A. A., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.017 · Cited by 64
Gries, J. J., Lazarus, J. V., Brennan, P., Siddiqui, M. S., Targher, G., Lang, C. C., Virani, S. S., Lavie, C. J., Isaacs, S. D., Arab, J. P., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00310-8 · Cited by 68
Self-citationBril, F., Leeming, D. J., Karsdal, M. A., Kalavalapalli, S., Barb, D., Lai, J., Rabe, M., & Cusi, K. (2019) · Diabetes Care · doi:10.2337/dc18-2578 · Cited by 52
Self-citationMetabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Self-citationMASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists
Cooreman, M. P., Vonghia, L., & Francque, S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111688 · Cited by 59
The current landscape of antifibrotic therapy across different organs: A systematic approach
Fuster‐Martínez, I., & Calatayud, S. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107245 · Cited by 63
Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2017.12.003 · Cited by 69
Cusi, K. (2019) · Hepatology · doi:10.1002/hep.30670 · Cited by 52
“(33) This reduction is also in agreement with the relative ~10%-20% reduction of IHTG observed in placebo arms of other controlled trials in patients with steatohepatitis (NASH).(7,34,35) Relative short duration of diabetes (~4 years) may have also promoted a better response than in previous studies, although the abso…”
ResultSelf-citationNASH: The Emerging Most Common Form of Chronic Liver Disease.
Tesfay, M., Goldkamp, W., & Neuschwander‐Tetri, B. A. (2018) · Europe PMC (PubMed Central) · Cited by 61
MASLD treatment—a shift in the paradigm is imminent
Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51
The growing range of complications of diabetes mellitus
Hamblin, P. S., Russell, A. W., Talic, S., & Zoungas, S. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.12.006 · Cited by 58
NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs
Caldwell, S. H. (2017) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2017.0103 · Cited by 56
“001).(34) Despite the track record in terms of efficacy with biopsy based evaluation,(35,36) safety concerns have dampened enthusiasm for use of the TZDs in NASH.”
BackgroundCurrent and emerging pharmacological therapy for non-alcoholic fatty liver disease
Eshraghian, A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i42.7495 · Cited by 53
Bril, F., Millán, L., Kalavalapalli, S., McPhaul, M. J., Caulfield, M. P., Martinez‐Arranz, I., Alonso, C., Ortiz Betes, P., Mato, J. M., & Cusi, K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13285 · Cited by 50
Self-citationAntidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
Tacelli, M., Celsa, C., Magro, B., Giannetti, A., Pennisi, G., Spatola, F., & Petta, S. (2018) · Pharmaceuticals · doi:10.3390/ph11040121 · Cited by 51
“[52] in which pioglitazone (compared to placebo) was administered for 18 months with a dosage of 45 mg/daily.”
MethodCusi, K. (2020) · Liver International · doi:10.1111/liv.14350 · Cited by 51
Self-citationTranscriptional Regulation in Non-Alcoholic Fatty Liver Disease
Steensels, S., Qiao, J., & Ersoy, B. A. (2020) · Metabolites · doi:10.3390/metabo10070283 · Cited by 58
Kasahara, N., Imi, Y., Amano, R., Shinohara, M., Okada, K., Hosokawa, Y., Imamori, M., Tomimoto, C., Kunisawa, J., Kishino, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46404-5 · Cited by 55
Emerging and future therapies for nonalcoholic steatohepatitis in adults
Mintziori, G., & Polyzos, S. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1225727 · Cited by 50
“results in patients with NASH and T2DM or prediabetes [16].”
ResultBajaj, H. S., Brown, R. E., Bhullar, L., Sohi, N., Kalra, S., & Aronson, R. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.08.001 · Cited by 50
Medical management of metabolic and cardiovascular complications after liver transplantation
Becchetti, C., Dirchwolf, M., Banz, V. M., & Dufour, J. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i18.2138 · Cited by 62
Jacques, V., Bolze, S., Hallakou‐Bozec, S., Czarnik, A. W., Divakaruni, A. S., Fouqueray, P., Murphy, A. N., Van der Ploeg, L. H. T., & DeWitt, S. (2021) · Hepatology Communications · doi:10.1002/hep4.1723 · Cited by 50
Metadata
- Authors
- Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., Webb, A., & Portillo-Sanchez, P.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- From University of Florida and Malcom Randall Veterans Affairs Medical Center, Gainesville, Florida, and University of Texas Health Science Center at San Antonio and Audie L. Murphy Veterans Affairs Medical Center, San Antonio, Texas.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-09-06
- Volume
- 165
- Issue
- 5
- Pages
- 305-315
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2470709274
- Cited by
- 1,024
- References
- 62
- Citations by year
- 2026: 82 · 2025: 108 · 2024: 109 · 2023: 103 · 2022: 116 · 2021: 131 · 2020: 108 · 2019: 85 · 2018: 85 · 2017: 67 · 2016: 27
- FWCI
- 82.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Funders
- U.S. Department of Veterans Affairs (1 I01 CX000167-01)
- American Diabetes Association
- Burroughs Wellcome Fund
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- pioglitazone, nonalcoholic steatohepatitis, prediabetes, type 2 diabetes, long-term treatment, hypocaloric diet, NASH resolution, liver fibrosis, hepatic triglyceride content, insulin sensitivity, insulin resistance, PPARγ agonists, drug safety, adverse events, liver histopathology, hepatic steatosis
- MeSH terms
- Pioglitazone, Transaminases, Diabetes Mellitus, Type 2, Diet, Reducing, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Liver, Male, Middle Aged, Prediabetic State, Triglycerides, Biomarkers, Weight Gain, Thiazolidinediones, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.